PETAGAYE REYES: Open Payments
NPI 1508563479 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,158 in 78 payments from 8 companies in 2025. Trend: 2023 $233 · 2024 $1,235 · 2025 $2,158
Food & beverage: $2,158
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $548 |
| E.R. Squibb & Sons, L.L.C. | 10 | $522 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $406 |
| ABBVIE INC. | 25 | $397 |
| Alkermes, Inc. | 2 | $146 |
| Janssen Pharmaceuticals, Inc | 3 | $84 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
Products named: COBENFY, CAPLYTA, VRAYLAR, REXULTI, ABILIFY ASIMTUFII, ABILIFY MAINTENA, LYBALVI, SPRAVATO.
Industry payments across PA — which companies pay providers there.
